Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

The companies also have an expanded three-year software agreement that will increase access for Novartis to Schrödinger’s ...

Novartis (NVS) has been beaten down lately with too much selling pressure. While the stock has lost 9.7% over the past four ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

Following their declassification, the former protected witnesses are now facing the political figures they had named as ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...

Schrödinger shares rise as they announce a research partnership and licensing agreement with Novartis AG. Schrödinger will ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple development ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

UBS analyst Matthew Weston maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF111.00. According to TipRanks, Weston is ranked #1736 out of 9162 analysts ...